Can-Fite to Participate in Panel Discussions on Latest Drug Developments in NASH at the 30th Annual ROTH Conference

On March 6, 2018 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, areported that it will be presenting at the 30th Annual ROTH Conference, being held on March 11-14, 2018 in Dana Point, California and participate in a NASH panel discussion titled "News is Great, Novel is Better" (Press release, Can-Fite BioPharma, MAR 6, 2018, View Source [SID1234524641]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Panel discussions on the latest topics and developments in NASH/PBC drug development span two days at the Roth Conference and are slated to feature 20 public and private companies in the field of liver diseases, 8 renowned Key Opinion Leaders, 3 NASH/PBC patients, and The American Liver Foundation.

In addition, Dr. Fishman will deliver the Company’s corporate presentation and provide updates on its lead drug candidate, Piclidenoson (CF101), currently in a Phase III trial for rheumatoid arthritis and is expected to enter a Phase III trial for psoriasis during 2018. The Company’s liver drug Namodenoson (CF102) is in a Phase II trial for patients with advanced liver cancer and is in a Phase II trial for the treatment of NAFLD/NASH.

The company recently provided an update on the progress of its ongoing Phase II NASH study and anticipates the completion of patient enrollment toward the end of 2018 and data release in the first half of 2019.

There is currently no U.S. FDA approved drug for the treatment of NASH, which is an addressable pharmaceutical market estimated to reach $35-40 billion by 2025.